These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8060800)

  • 21. [Observations regarding internet-based applications in gastroenterology specialty practices--aspects of quality control].
    Ose C; Hirche H; Jöckel KH; Küppers B; Warth L; Rammler B
    Stud Health Technol Inform; 2000; 77():348-52. PubMed ID: 11187572
    [No Abstract]   [Full Text] [Related]  

  • 22. Lansoprazole.
    Med Lett Drugs Ther; 1995 Jul; 37(953):63-4. PubMed ID: 7603391
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment of gastroesophageal reflux: the role of proton pump inhibitors.
    Schulman MI; Orlando RC
    Adv Intern Med; 1995; 40():273-302. PubMed ID: 7747649
    [No Abstract]   [Full Text] [Related]  

  • 24. PPIs vs H2RAs for erosive reflux esophagitis.
    King VJ
    J Fam Pract; 1998 Mar; 46(3):199-200. PubMed ID: 9519012
    [No Abstract]   [Full Text] [Related]  

  • 25. Balanced perspective essential in erosive oesophagitis treatment.
    Gillessen A
    Aliment Pharmacol Ther; 2005 Nov; 22(9):889-90; author reply 890-1. PubMed ID: 16225500
    [No Abstract]   [Full Text] [Related]  

  • 26. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
    Giral A; Celikel CA; Ozdogan O; Tözün N; Ulusoy NB; Kalayci C
    J Gastroenterol Hepatol; 2005 Dec; 20(12):1886-91. PubMed ID: 16336449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The Lansoprazole Maintenance Study Group.
    Sontag SJ; Kogut DG; Fleischmann R; Campbell DR; Richter J; Haber M
    Am J Gastroenterol; 1996 Sep; 91(9):1758-65. PubMed ID: 8792694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Maintenance therapies for reflux esophagitis.
    Grey MR
    N Engl J Med; 1996 Feb; 334(9):600-1. PubMed ID: 8569838
    [No Abstract]   [Full Text] [Related]  

  • 29. Reflux esophagitis in recurrent abdominal pain.
    Narula PB; Rajeshwari K; Malhotra V; Mittal SK
    Trop Gastroenterol; 2002; 23(4):202-5. PubMed ID: 12833714
    [No Abstract]   [Full Text] [Related]  

  • 30. Omeprazole versus ranitidine in erosive oesophagitis.
    Zeitoun P; Desjars De Keranroué N; Isal JP
    Lancet; 1987 Sep; 2(8559):621-2. PubMed ID: 2887900
    [No Abstract]   [Full Text] [Related]  

  • 31. Ranitidine in the management of gastro-oesophageal reflux disease.
    Nelis GF
    Neth J Med; 1985; 28(5):197-200. PubMed ID: 3892319
    [No Abstract]   [Full Text] [Related]  

  • 32. [Reflux esophagitis. Step-down instead of step-up].
    MMW Fortschr Med; 2006 Nov; 148(47):56-7. PubMed ID: 17168191
    [No Abstract]   [Full Text] [Related]  

  • 33. Patients vote with their feet for 'On demand' rabeprazole in the maintenance treatment phase of reflux oesophagitis.
    Tan VP; Wong BC
    Aliment Pharmacol Ther; 2010 Jul; 32(2):305-7; author reply 307-8. PubMed ID: 20636626
    [No Abstract]   [Full Text] [Related]  

  • 34. Comparison of ranitidine, domperidone maleate and ranitidine + domperidone maleate in the short-term treatment of reflux oesophagitis.
    Masci E; Testoni PA; Passaretti S; Guslandi M; Tittobello A
    Drugs Exp Clin Res; 1985; 11(10):687-92. PubMed ID: 3915459
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Omeprazole is more cost-effective than ranitidine in reflux esophagitis].
    Lindberg G; Jönsson B
    Lakartidningen; 1992 Jul; 89(30-31):2530-3. PubMed ID: 1507987
    [No Abstract]   [Full Text] [Related]  

  • 36. [H2-blockers in reflux-esophagitis].
    Berstad A
    Tidsskr Nor Laegeforen; 1983 Jul; 103(19-21):1439-41. PubMed ID: 6138879
    [No Abstract]   [Full Text] [Related]  

  • 37. Fundic gland polyps: three other case reports suggesting a possible association with acid suppressing therapy.
    Van Vlierberghe H; De Vos M; De Cock G; Cuvelier C; Elewaut A
    Acta Gastroenterol Belg; 1997; 60(3):240-2. PubMed ID: 9396183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Prognostic markers in reflux esophagitis better than wrapped up recommendations].
    Lindberg G; Jönsson B
    Lakartidningen; 1992 Dec; 89(49):4243-4. PubMed ID: 1461046
    [No Abstract]   [Full Text] [Related]  

  • 39. [Our experience in the treatment of reflux esophagitis with histamine H2 receptor antagonists].
    Cappelli J; Morobe J; Van Laethem A; Musin L
    Acta Chir Belg; 1983; 83(6):440-3. PubMed ID: 6318487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment with ranitidine in reflux esophagitis].
    Balanzoni S; Bagioni P; Turicchia GU; Campagnoni R; Sansone G; Tampieri I
    Minerva Dietol Gastroenterol; 1986; 32(1):35-8. PubMed ID: 3703318
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.